Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 26, 1997Archives of Internal Medicine

Heart Failure Treatment With Angiotensin-Converting Enzyme Inhibitors in Hospitalized Medicare Patients in 10 Large States

View Full Paper
Ask AI
Bookmark
Share

Key result

ACE inhibitors were prescribed at discharge to 55% (95% CI 54-56%) of hospitalized Medicare patients with heart failure, and 73% (95% CI 71-75%) of ideal candidates without contraindications.

Why the study?

What is the rate of ACE inhibitor prescription at discharge among Medicare patients hospitalized with heart failure?

Population

6,749 Medicare patients aged 65 years and older admitted to acute care hospitals with a principal diagnosis…

Design

Cross-sectional

Discussion

Loading...

Member takes

Implication

Documents gaps in ACE inhibitor use among hospitalized heart failure patients; leaves open reasons for non-prescription and targeted improvement strategies.

Study Design

Type

Observational (n=6,749)

Multicenter

Yes

Structured PICO

What is the rate of ACE inhibitor prescription at discharge among Medicare patients hospitalized with heart failure?

P
Population
6,749 Medicare patients aged 65 years and older admitted to acute care hospitals with a principal diagnosis of heart failure, discharged in 1993 and 1994 across 10 populous US states.
I
Intervention
Prescription of ACE inhibitors at discharge
O
Outcome
Use of ACE inhibitors at discharge and documentation of cardiac ejection fractions

This study highlights the underuse of ACE inhibitors in eligible Medicare patients hospitalized with heart failure, with up to one quarter of ideal candidates not receiving the therapy at discharge.

Cite This Study

A 1997 study conducted an observational in Heart failure (n=6,749). Angiotensin-converting enzyme (ACE) inhibitors was evaluated on Use of ACE inhibitors at discharge (95% CI 54-56). ACE inhibitors were prescribed at discharge to 55% (95% CI 54-56%) of hospitalized Medicare patients with heart failure, and 73% (95% CI 71-75%) of ideal candidates without contraindications.

synapsesocial.com/papers/6a07fbd5686e45fdbcfe0ea5https://doi.org/10.1001/archinte.1997.00440310067007

Topics

HFrEF treatmentHeart failureHeart failure hospitalizationHFpEF management
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. The Large State Peer Review Organization Consortium1997 · 19 citations
  2. 2Age-Related Underutilization of Angiotensin-Converting Enzyme Inhibitors in Older Hospitalized Heart Failure Patients2002 · 30 citations
  3. 3Determinants of Mortality in Elderly Patients With Heart Failure1998 · 70 citations
  4. 4The use of angiotensin-converting enzyme inhibitors in the treatment of heart failure in hospital practice1997 · 15 citations
  5. 5Use of angiotensin-converting enzyme inhibitors in elderly patients with heart failure1998 · 14 citations